242 related articles for article (PubMed ID: 35732748)
1. A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices.
Rifkin RM; Crawford J; Mahtani RL; Dale DC; Narang M; MacLaughlin WW; Huynh C; Gawade PL; Lewis S; DeCosta L; Lawrence T; Belani R
Support Care Cancer; 2022 Oct; 30(10):7913-7922. PubMed ID: 35732748
[TBL] [Abstract][Full Text] [Related]
2. A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.
Mahtani RL; Belani R; Crawford J; Dale D; DeCosta L; Gawade PL; Huynh C; Lawrence T; Lewis S; MacLaughlin WW; Narang M; Rifkin R
Support Care Cancer; 2022 Jul; 30(7):6135-6144. PubMed ID: 35426046
[TBL] [Abstract][Full Text] [Related]
3. Two decades of pegfilgrastim: what have we learned? Where do we go from here?
De Oliveira Brandao C; Lewis S; Sandschafer D; Crawford J
Curr Med Res Opin; 2023 May; 39(5):707-718. PubMed ID: 36976784
[TBL] [Abstract][Full Text] [Related]
4. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
[No Abstract] [Full Text] [Related]
5. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
[TBL] [Abstract][Full Text] [Related]
6. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
Brito M; Esteves S; André R; Isidoro M; Moreira A
Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
[TBL] [Abstract][Full Text] [Related]
7. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
[TBL] [Abstract][Full Text] [Related]
8. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy.
Wang XJ; Tang T; Farid M; Quek R; Tao M; Lim ST; Wee HL; Chan A
PLoS One; 2016; 11(2):e0148901. PubMed ID: 26871584
[TBL] [Abstract][Full Text] [Related]
9. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy.
Schenfeld J; Gong T; Henry D; Kelsh M; Gawade P; Peng Y; Bradbury BD; Li S
Support Care Cancer; 2022 Jul; 30(7):6327-6338. PubMed ID: 35482126
[TBL] [Abstract][Full Text] [Related]
10. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
Wang L; Baser O; Kutikova L; Page JH; Barron R
Support Care Cancer; 2015 Nov; 23(11):3131-40. PubMed ID: 25821144
[TBL] [Abstract][Full Text] [Related]
11. Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment.
McBride A; MacDonald K; Fuentes-Alburo A; Abraham I
J Med Econ; 2021; 24(1):598-606. PubMed ID: 33866947
[TBL] [Abstract][Full Text] [Related]
12. A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants.
Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
Adv Ther; 2024 Mar; 41(3):991-1009. PubMed ID: 38180721
[TBL] [Abstract][Full Text] [Related]
13. Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.
Cerchione C; De Renzo A; Di Perna M; Della Pepa R; Pugliese N; Catalano L; Pane F; Picardi M
Support Care Cancer; 2017 Mar; 25(3):839-845. PubMed ID: 27812763
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study.
Wang CY; Vouri SM; Park H; Heldermon CD; Brown JD
J Manag Care Spec Pharm; 2023 Feb; 29(2):119-127. PubMed ID: 36705287
[No Abstract] [Full Text] [Related]
15. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy.
Gawade PL; Li S; Henry D; Smith N; Belani R; Kelsh MA; Bradbury BD
Support Care Cancer; 2020 Sep; 28(9):4413-4424. PubMed ID: 31919669
[TBL] [Abstract][Full Text] [Related]
16. Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis.
McBride A; Campbell K; Li E; Schroader B; Campbell D; Wang W
J Manag Care Spec Pharm; 2021 Sep; 27(9):1230-1238. PubMed ID: 33929269
[No Abstract] [Full Text] [Related]
17. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.
Gebremariam GT; Fentie AM; Beyene K; Sander B; Gebretekle GB
BMC Health Serv Res; 2022 Dec; 22(1):1600. PubMed ID: 36585648
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.
Cooper KL; Madan J; Whyte S; Stevenson MD; Akehurst RL
BMC Cancer; 2011 Sep; 11():404. PubMed ID: 21943360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]